Dendritic cell integrin expression patterns regulate inflammation in the rheumatoid arthritis joint by Schittenhelm, Leonie et al.
Original Article
Dendritic cell integrin expression patterns regulate
inflammation in the rheumatoid arthritis joint
Leonie Schittenhelm1,2,3, Jamie Robertson1, Arthur G. Pratt2,3,4,
Catharien M. Hilkens2,3 and Vicky L. Morrison1,3
Abstract
Objectives. Immune dysregulation contributes to the development of RA. Altered surface expression patterns of
integrin adhesion receptors by immune cells is one mechanism by which this may occur. We investigated the role
of b2 integrin subunits CD11a and CD11b in dendritic cell (DC) subsets of RA patients.
Methods. Total b2 integrin subunit expression and its conformation (‘active’ vs ‘inactive’ state) were quantified in
DC subsets from peripheral blood (PB) and SF of RA patients as well as PB from healthy controls. Ex vivo stimula-
tion of PB DC subsets and in vitro-generated mature and tolerogenic monocyte-derived DCs (moDCs) were utilized
to model the clinical findings. Integrin subunit contribution to DC function was tested by analysing clustering and
adhesion, and in co-cultures to assess T cell activation.
Results. A significant reduction in total and active CD11a expression in DCs in RA SF compared with PB and,
conversely, a significant increase in CD11b expression was found. These findings were modelled in vitro using
moDCs: tolerogenic moDCs showed higher expression of active CD11a and reduced levels of active CD11b com-
pared with mature moDCs. Finally, blockade of CD11b impaired T cell activation in DC–T cell co-cultures.
Conclusion. For the first time in RA, we show opposing expression of CD11a and CD11b in DCs in environments
of inflammation (CD11alow/CD11bhigh) and steady state/tolerance (CD11ahigh/CD11blow), as well as a T cell stimula-
tory role for CD11b. These findings highlight DC integrins as potential novel targets for intervention in RA.
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Introduction
In autoimmune diseases such as RA, genetic risk factors
together with environmental factors lead to a breach in
immune tolerance to self-antigens. The following asymp-
tomatic phase, where T and B cells become activated
and auto-antibody is produced, can last for months or
years before presenting as clinical symptoms [1].
Currently, there is no cure for RA: therapeutics control
disease activity and treat the symptoms [2], but do not
restore immune tolerance.
Dendritic cells (DCs) are the key cell type that controls
the balance between immune activation and tolerance.
Through direct cellular interactions, DCs direct T cell tol-
erance under steady-state conditions and induce T cell
activation against pathogens. It is likely that DCs con-
tribute to both the initiation and perpetuation of RA
(reviewed in [3]). First, DCs are the major antigen-
presenting cell population, priming naı̈ve T cells in sec-
ondary lymphoid tissues. In RA, these activated T cells
are major contributors to local (joint) and systemic in-
flammation. Second, DCs contribute to the perpetuation
of RA by acting locally in the inflamed joint. They pre-
sent antigen within the joint tissue that promotes auto-
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reactive T cell responses [4], produce a myriad inflam-
matory factors that drive innate cell activation and ef-
fector responses [5, 6], and potentially contribute to the
development of ectopic lymphoid structures [7].
Different DC subsets are specialized to direct different
types of T cell response [8]: conventional DC1 (cDC1)
are capable of cross presentation of antigen to CD8þ T
cells; cDC2 are dynamic cells that initiate different types
of CD4þ T cell responses (e.g. Th1, Th2, Th17) depend-
ing on the inflammatory signals they receive; whilst plas-
macytoid DC (pDC) rapidly produce type I IFN,
promoting CD8þ T cell activation. Each of these DC
subsets is known to infiltrate the joint during RA, where
their inflammatory phenotype suggests they contribute
to pathology [9]. Altered behaviour of DCs is likely a key
factor in the development of autoimmunity, but also
presents a potential therapeutic opportunity.
Integrins are heterodimeric adhesion receptors pre-
sent on the surface of cells that bind ligands on other
cells and extracellular matrix components. The b2 integ-
rin family, consisting of four members (the b2 subunit,
CD18, paired with one of four a subunits aL CD11a, aM
CD11b, aX CD11c, or aD CD11d), are expressed exclu-
sively by leukocytes and control various aspects of DC
function [10]. In mouse models, b2 integrins have been
shown to directly regulate the activation status of DCs
in steady state [11], thus restricting T cell priming [11]
and limiting inflammation [12]. Additionally, b2 integrins
expressed by DCs regulate contact dynamics with T
cells thereby influencing T cell priming [13, 14].
Importantly, the involvement of b2 integrins in the regula-
tion of DC subset function in humans is yet to be char-
acterized. However, their role in immune regulation is
supported by evidence from patients with b2 integrin
deficiencies, termed leukocyte adhesion deficiencies,
where increased incidence of IBD has been reported
[15, 16].
Given the clear role for b2 integrins in regulating DC
function, we hypothesized that the integrin expression
and/or conformation profile in infiltrating DCs in the RA
joint contributes to the failure of synovitis to resolve in
this condition. Our ‘first in RA’ study demonstrates
opposing expression of the integrin subunits CD11a and
CD11b in DCs in environments of inflammation (includ-
ing RA) and steady state/tolerance, potentially highlight-
ing these integrin subunits as novel targets for
intervention in RA treatment.
Methods
Subjects
RA patient volunteers were recruited from routine out-
patient clinics at Gartnavel General Hospital (National
Health Service Greater Glasgow and Clyde). All patients
fulfilled classification criteria for RA according to inter-
national criteria [17] and provided full written informed
consent. Healthy donors were recruited locally with full
written informed consent. The study complies with the
Declaration of Helsinki and was approved by the
University of Glasgow Research Ethics Committee [ref-
erence numbers 2012073 for healthy control peripheral
blood (PB); 14/WS/1035 and 16/WS/0207 for RA patient
samples]. All samples were anonymized using a unique
identifying number.
Cell isolation
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from PB, SF or buffy coat by density gradient cen-
trifugation utilizing Lymphoprep (Axis-Shield POC AS,
Oslo, Norway) on the date of draw. To isolate naı̈ve
CD4þ T cells (CD4þCD45RO–), buffy coat was enriched
for T cells using the Rosettesep Human CD4þ enrich-
ment cocktail (Stemcell Technologies, Grenoble, France)
before excluding CD45ROþ cells using anti-CD45RO
magnetic microbeads (Miltenyi Biotec, Bergisch
Gladbach, Germany) according to the manufacturer’s
instructions. CD14þ monocytes were isolated by positive
selection according to manufacturer guidelines (Miltenyi
Biotec, Bergisch Gladbach, Germany).
PBMC stimulation
PBMCs were plated into 48 well plates (Corning, New
York, NY, USA) at 1.5 106 cells/well and stimulated for
18 h at 37C with 5% CO2: untreated, lipopolysacchar-
ide (LPS; 100 ng/ml, Sigma-Aldrich, St Louis, MO, USA),
IL-1bþTNF (both 10 ng/ml, Immunotools, Friesoythe,
Germany), IL-10þTGF-b (both 10 ng/ml, Immunotools,
Friesoythe, Germany). All stimulations were performed in
duplicate.
Generation of moDCs
Monocyte-derived DCs (moDCs) were generated as pre-
viously described [18]. Briefly, isolated CD14þ mono-
cytes were cultured in IL-4 and GM-CSF (50 ng/ml each;
ImmunoTools, Friesoythe, Germany). Tolerogenic
moDCs (tolDCs) received 106 M dexamethasone on
day 3, which was refreshed on day 6 with the further
addition of 1010 M vitamin D3 and 0.1 mg/ml of LPS
(Sigma-Aldrich, St Louis, MO, USA). Mature moDCs
(matDCs) received 0.1mg/ml LPS on day 6 of culture.
Immature moDCs received no stimuli. All cells were har-
vested on day 7 after incubation on ice for 60 min to in-
crease cell detachment.
Quantification of b2 integrin expression by flow
cytometry
Staining of total and active b2 integrin subunits was per-
formed at 37C for 30 min. A negative control containing
no integrin antibodies, a negative control containing iso-
type control antibodies and a positive control treated
with phorbol myristate acetate (concurrently with anti-
body staining) were included in every experiment. All
flow cytometry staining and washing steps were exe-
cuted using cold FACS buffer, consisting of PBS plus
3% foetal calf serum, 0.01% sodium azide (Sigma-
Aldrich, St Louis, MO, USA) and 1 mM EDTA, and in the
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presence of human IgG (Sigma-Aldrich, St Louis, MO,
USA) and 1 mM magnesium chloride (Sigma-Aldrich, St
Louis, MO, USA). For b2 integrin detection the following
antibodies were used (Biolegend, San Diego, CA, USA;
unless otherwise stated): CD11a active (MEM83,
NovusBio, Littleton, CO, USA), CD11a total (HI111),
CD11b active (CBRM1/5), and CD11b total (ICRF44).
The following antibodies were used to define the popu-
lations of interest: CD1c, CD11c, CD16, CD141
(Biolegend, San Diego, CA, USA), CD14, CD45, HLA-DR
(BD Biosciences, San Jose, CA, USA) and CD3, CD19,
CD20 and CD56 (ebioscience, San Diego, CA, USA).
The DC gating strategy is shown in supplementary Fig.
S1, available at Rheumatology online. All flow cytometry
samples were acquired using a BD Fortessa and data
was analysed using Flowjo software (BD Biosciences,
San Jose, CA, USA).
moDC–T cell co-cultures
Naı̈ve CD4þ T cells were stained with 5 mM CellTrace
Violet Proliferation Dye (CTV, Thermo Fisher Scientific,
Waltham, MA, USA) according to the manufacturer’s
instructions. moDC (matDC or tolDC; 5104 cells/well)
were co-cultured with allogeneic naı̈ve CD4þ T cells
(5105 cells/well) in 48 well plates (Corning, New York,
NY, USA) at 37C, 5% CO2. Where indicated, 20mg/ml
CD11b blocking antibody or relevant isotype control
(both Biolegend, San Diego, CA, USA) were added.
CD11b blocking antibody/isotype control were replen-
ished on day 4. On day 6, T cell proliferation was ana-
lysed by flow cytometry and supernatants were
collected for IFNc and IL-10 quantification by ELISA
(Biolegend, San Diego, CA, USA) according to the man-
ufacturer’s instructions.
Analysis of moDC clustering
moDC clustering was analysed on a Leica DMi8 micro-
scope (Leica Microsystems, Wetzlar, Germany) with a
live cell chamber maintaining 37C and 5% CO2.
matDCs and tolDCs were plated onto glass-bottomed
24-well plates (200 000 cells/well) and imaged 6 h later.
A cellprofiler pipeline was designed to identify clusters
of cells and single non-clustered cells for quantification
of number, size and radius (supplementary Fig. S2,
available at Rheumatology online). Clusters were defined
as cells that had neighbouring cells with touching
borders.
Adhesion assay
Fibronectin (10 mg/ml, R&D Systems, Minneapolis, MN,
USA) was coated overnight at 4C onto COSTAR 96
well high-binding assay plates (Corning, New York, NY,
USA). Wells were blocked with 1% milk for 1 h 15 min at
37C. moDCs were resuspended in adhesion medium
consisting of RPMI 1640, 0.1% BSA, 20 mM HEPES (pH
7.25) and 2 mM magnesium chloride (all from Sigma-
Aldrich, St Louis, MO, USAs), before being added to
wells at 25 103 moDCs/well in duplicate or triplicate.
Cells were allowed to adhere for 15 min at 37C before
plates were gently washed. Cell lysis and detection was
performed according to Matthews et al. [19].
Statistical analysis
Prism software (Graphpad, San Diego, CA, USA) was
used for all statistical analysis. All datasets were sub-
jected to testing for normal distribution using the
Shapiro–Wilk normality test. Normally distributed data
underwent a paired or unpaired Student’s t-test (for two
groups) or one-way ANOVA (for more than two groups).
If data were not normally distributed, a Wilcoxon
matched-pairs signed rank test was used if comparing
two paired groups, otherwise a Mann–Whitney U test
was used. Graphs show mean (S.D.) unless stated other-
wise in the legend. P-values shown are as follows: *P <
0.05, **P < 0.01, ***P < 0.001.
Results
CD11a expression by DCs is strikingly reduced in
the RA joint, while CD11b expression is increased
Expression of total integrins (i.e. low- and high-affinity
forms) and active integrins (only the high-affinity con-
formation that can mediate binding) was measured in
RA patients with active disease (DAS28 ESR >3.2), RA
patients in remission (DAS28 ESR <2.6) and healthy
controls. Three different DC populations were analysed,
namely cDC1, cDC2 and pDC (gating strategy shown in
supplementary Fig. S1, available at Rheumatology on-
line), which are known to infiltrate the RA joint and pro-
mote T cell activation [9].
Integrin expression in circulating DC populations iso-
lated from RA patients was equivalent to that in healthy
controls, regardless of the integrin subunit in question
(CD11a or CD11b), the conformation of the integrin (total
or active), the DC population (cDC1, cDC2 or pDC) or
the inflammatory burden (active RA or remission) (sup-
plementary Fig. S3, clinical characteristics shown in
supplementary Table S1, both available at
Rheumatology online). However, analysis of matched SF
and PB samples identified striking changes in integrin
subunit expression by DCs (Fig. 1; clinical characteris-
tics shown in supplementary Table S2, available at
Rheumatology online). Expression of both total and ac-
tive CD11a was significantly decreased in cDC1 and
cDC2 cells, but not pDCs, isolated from SF compared
with PB (Fig. 1A and B), whilst expression of total and
active CD11b was significantly increased in SF com-
pared with PB in cDC2 cells only (Fig. 1C and D).
Together, these data indicate that b2 integrin a subunits
CD11a and CD11b are differentially regulated in DCs in
the RA joint.
Dendritic cell integrin expression patterns regulate inflammation in the rheumatoid arthritis joint
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FIG. 1 Reduced CD11a and increased CD11b expression in cDC2s in SF compared with PB in RA
Expression of total and active CD11a (A, B) and CD11b (C, D) comparing PB (dark grey) versus matched SF (light
grey) from the same RA patient in cDC1, cDC2 and pDCs. Representative histograms (A and C) and pooled data dis-
playing MFI (B and D) are shown. n¼5 paired samples. As n was too small for normality testing, paired Student’s t-
test was used to calculate statistical significance; *P< 0.05, **P< 0.01, ***P<0.001. cDC: conventional dendritic cell;
pDC: plasmacytoid dendritic cell; PB: peripheral blood; MFI: median fluorescence intensity.
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CD11a expression is reduced in DCs in response to
inflammatory stimuli
Next, we questioned whether these changes in integrin
subunit expression could be modelled in vitro with
short-term stimulation. Given that the joint is the main
focus of inflammation in RA, we hypothesized that DCs
would lose CD11a in response to pro-inflammatory stim-
uli and show an increase in CD11b, in line with our find-
ings in SF DCs. To test this hypothesis, unsorted
PBMCs from healthy subjects (containing immature
DCs) were treated with pro- (LPS, IL-1/TNF-a) and anti-
(IL-10/TGF-b) inflammatory stimuli, and the effect on ex-
pression of total and active integrin subunits was meas-
ured in each DC subset present within the PBMC
population (Fig. 2).
Total CD11a expression was significantly reduced in
cDC1 and cDC2 DCs treated with the pro-inflammatory
stimuli, LPS and IL-1/TNF-a when compared with the
untreated control, while total CD11a expression was not
affected by IL-10/TGF-b treatment (Fig. 2A), mirroring
our observations in RA patient PB vs the inflammatory
milieu of the joint. In contrast, CD11a conformation was
not significantly affected by the addition of pro- or anti-
inflammatory stimuli in either cDC1 or cDC2 DCs, with
neither expression nor conformation affected in pDCs.
These data indicate that CD11a expression is reduced
in cDCs in inflammatory environments.
The predicted increase in total and/or active CD11b in
response to inflammatory stimuli was not observed in
any of the DC subsets. Indeed, total CD11b expression
by cDC1 cell exposed to such stimuli was paradoxically
reduced compared with that in untreated control cells
(Fig. 2B). Total CD11b expression was also reduced in
cDC1 cells treated with IL-10/TGF-b.
Together, these data suggest exposure to inflamma-
tory stimuli have the potential to shape patterns of integ-
rin expression in RA.
tolDCs display increased CD11a and reduced
CD11b expression compared with matDCs
Due to the widespread use of moDCs as an ex vivo
model of DCs, together with the recognized therapeutic
potential of tolDCs in RA (reviewed in [20] and [21]), we
next determined whether alterations in DC integrin sub-
unit expression could be modelled in matDCs and
tolDCs. matDCs and tolDCs were generated by in vitro
culture of monocytes and their phenotype was con-
firmed by flow cytometry (supplementary Fig. S4A–C,
available at Rheumatology online [22, 23]). Importantly,
tolDCs were confirmed to induce reduced levels of T
cell activation compared with matDCs (supplementary
Fig. S4D, available at Rheumatology online).
FIG. 2 CD11a expression is reduced in DCs in response to inflammatory stimuli
PBMCs were isolated from healthy controls and either left untreated (none) or stimulated with IL-1/TNF-a (10 ng/ml
each), LPS (100 ng/ml) or IL-10/TGF-b (10 ng/ml each) for 18 h. cDC1, cDC2 and pDCs were gated as per the gating
strategy shown in supplementary Fig. S1 available at Rheumatology online. MFI of expression of integrins CD11a (A)
and CD11b (B) is shown. n¼8, pooled from two independent experiments. All data are normally distributed.
Repeated measures matched one-way ANOVA was used to calculate statistical significance; *P< 0.05, **P<0.01,
***P< 0.001. DC: dendritic cell; PBMC: peripheral blood mononuclear cell; LPS: lipopolysaccharide; cDC: convention-
al DC; pDC: plasmacytoid DC; MFI: median fluorescence intensity.
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Expression of CD11a and CD11b was quantified in
matDCs and tolDCs (Fig. 3). No differences in expres-
sion of total CD11a or total CD11b were observed be-
tween matDCs and tolDCs. However, tolDCs expressed
significantly increased levels of active CD11a, but signifi-
cantly reduced levels of active CD11b compared with
matDCs. Together, these data support the notion that
the inflammatory phenotype of DCs is reciprocally linked
to their CD11a/b activity.
tolDCs show reduced clustering and adhesion
compared with matDCs
Using monocyte-derived matDCs and tolDCs as a
model of endogenous DCs under inflammatory and tol-
erogenic conditions, respectively [24], we next deter-
mined the functional impact of differential expression of
the integrin subunits, CD11a and CD11b, in DCs. During
immune responses in vivo, DCs and T cells form clusters
in secondary lymphoid tissues that promote long-lived
immune interactions and T cell activation [25]. Therefore,
the clustering behaviour of moDCs was quantified by
imaging on glass slides (Fig. 4A; supplementary Fig. S2,
available at Rheumatology online). matDCs showed
increased clustering compared with tolDCs (Fig. 4A).
Quantification of cluster size confirmed that matDCs
form clusters with significantly larger area and mean
FIG. 3 tolDCs display increased CD11a and reduced
CD11b expression compared with matDCs
Monocyte-derived mature (matDCs) and tolerogenic
(tolDCs) DC expression of b2 integrin subunits CD11a
and CD11b is shown. Representative histograms are
shown for active integrin subunit expression only, with
matDCs in dark grey and tolDCs in light grey. n¼13.
Total CD11a data are not normally distributed; Wilcoxon
matched-pairs signed rank test was used to calculate
statistical significance. All other data were normally dis-
tributed; paired Student’s t-test was used; *P<0.05.
DC: dendritic cell; MFI: median fluorescence intensity.
FIG. 4 tolDCs show reduced clustering and adhesion
compared with matDCs
Clustering analysis (see supplementary Fig. S2 available
at Rheumatology online) was performed on monocyte-
derived mature (matDCs) and tolerogenic (tolDCs) den-
dritic cells plated on glass slides for 6 h. (A)
Representative bright field microscopy images. (B) Area
(number of pixels per cluster), where a cluster size cut-
off was set as 40 lm (approx. 2 cell diameter). (C)
Median radius, where a cluster size cut-off was set as
20 lm radius. (B and C) Mature¼ 1493, toler-
ogenic¼2405 individual clusters; not normally distrib-
uted; Mann–Whitney U test. (D, E) Number of clusters
and unclustered cells. Mature n¼29, tolerogenic n¼28;
data are normally distributed; Student’s t-test. (F)
Adhesion of matDCs and tolDCs to fibronectin. n¼10;
not normally distributed; Wilcoxon test. For (A–F), three
independent experiments (different donors) were per-
formed. Mean (S.D.) is shown except in (B) and (C),
where median and interquartile range is shown. In all
cases *P< 0.05, **P< 0.01, ***P< 0.001.
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radius compared with tolDCs (Fig. 4B and C). To further
quantify clustering ability of different moDC subtypes,
the number of clusters formed and number of unclus-
tered cells was compared (Fig. 4D and E). The data
show that matDCs formed significantly fewer clusters
compared with tolDCs, but that they are large in size, as
shown in Fig. 4B. The number of unclustered cells was
equivalent between matDCs and tolDCs (Fig. 4E). These
data demonstrate that clustering is significantly reduced
in tolerogenic compared with mature moDCs.
Considering the differences in integrin subunit expres-
sion by matDCs and tolDCs and the striking effects on
cell clustering, we next measured moDC adhesiveness
to the matrix component fibronectin. The adhesiveness
of DCs to matrix is thought to inversely correlate with
their ability to migrate to the T cell zones of secondary
lymphoid tissues [11]. Adhesion to fibronectin is medi-
ated by several integrin subunits, with CD11b having a
higher affinity than CD11a [26]. Adhesion to fibronectin
was reduced in tolDCs compared with matDCs
(Fig. 4D).
Together, these data suggest that alterations in integ-
rin activity in tolDC result in reduced cell–cell clustering
and adhesion to fibronectin compared with matDC.
Blockade of CD11b on matDCs reduces their ability
to induce T cell activation
Finally, we investigated the functional impact of b2 integ-
rin subunit expression by DCs on T cell activation. To
this end, the integrin subunit CD11b, which, unlike
CD11a, is not expressed by T cells (supplementary Fig.
S5, available at Rheumatology online), was blocked in
DC–T cell co-cultures containing either matDCs or
tolDCs together with allogeneic naı̈ve CD4þ T cells.
Blockade of CD11b on matDCs resulted in significantly
reduced T cell proliferation (Fig. 5A) and production of
the Th1 cytokine IFNc (Fig. 5B). A similar trend of
reduced T cell proliferation was observed in tolDC cul-
tures with CD11b blockade (Fig. 5A), and reduced IFNc
production was also observed (Fig. 5B). IL-10 produc-
tion was not affected by CD11b blockade in either
moDC–T cell co-culture (Fig. 5C), though the source of
this IL-10 (DCs or T cells) was not confirmed.
These data reveal that CD11b expressed by matDCs
functions to promote T cell priming. In turn, these find-
ings suggest that the reduction of active CD11b in
tolDCs when compared with matDCs may contribute to
their tolerogenic function.
Discussion
Using RA patient samples and in vitro DC models, this
study demonstrates for the first time that b2 integrin
subunits CD11a and CD11b have distinct and opposing
roles in human DCs: high CD11a expression in steady
state/tolerogenic DCs supports previous findings of an
immunoregulatory role, while high CD11b was observed
in inflammatory DCs and promoted T cell activation.
These findings highlight the integrin expression pheno-
type of DCs as a potentially targetable regulator of tis-
sue inflammation in immune-mediated diseases such as
RA.
We consistently found reduced expression of CD11a
(either total, active or both) by DCs in inflammatory con-
texts. This was true (i) in cDC1 and cDC2 cells from RA
patient SF compared with circulating PB DCs; (ii) in cir-
culating cDC1 and cDC2 cells treated with pro-
inflammatory stimuli LPS or IL-1/TNF-a; and (iii) in
monocyte-derived matDCs compared with tolDCs. The
down-regulation of CD11a in response to both short-
term stimulation with cytokines and pathogen-derived
factors (LPS) in vitro and chronic inflammation in vivo (in
RA patient SF) indicate that this is likely a general re-
sponse to inflammation rather than an RA-specific phe-
nomenon. In the future, it will be important to determine
whether other factors present in the RA joint such as
cytokines (e.g. IL-6), growth factors (e.g. GM-CSF), and
host-derived stress molecules (e.g. HSPs) induce similar
changes in integrin expression profiles in DCs. Our
FIG. 5 Blockade of CD11b on matDCs reduces their
ability to induce T cell activation
Anti-CD11b blocking antibody (M1/70) or isotype control
(iso; rat IgG2bj) was added to DC–T cell co-cultures.
(A) T cell proliferation was quantified on day 6 of culture
by analysis of Cell Trace Violet dilution. Concentrations
of IFNc (B) and IL-10 (C) in co-culture supernatants on
day 6 were measured by ELISA. n¼ 9 moDCs, cultured
with n¼3 naı̈ve T cells. In (A) and (C), data are normally
distributed; paired Student’s t-test was performed. In (B)
data are not normally distributed; Wilcoxon test was
performed. *P<0.05, **P<0.01. DC: dendritic cell;
moDC: monocyte-derived DC; matDC: mature moDC;
tolDC: tolerogenic moDC.
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current model is that CD11a plays a regulatory role in
DCs that is down-regulated in the context of inflamma-
tion. Although the number of studies is few, previous
evidence does support a functional immunoregulatory
role for CD11a on DCs: constitutive activation of CD11a
on murine bone marrow-derived DCs reduced their abil-
ity to stimulate T cell proliferation both in vitro and
in vivo [13]; meanwhile, high levels of ‘shed’ CD11a
have been reported in synovial effusions [27], suggesting
that CD11a is actively lost from the cell surface in re-
sponse to inflammatory stimuli. As technical challenges
prevented us from blocking DC CD11a in the moDC–T
cell co-cultures (as T cells highly express CD11a; sup-
plementary Fig. S5, available at Rheumatology online),
further studies are required to fully explore the direct
and indirect functional effects of CD11a expression by
DCs in T cell activation and tolerance.
Conversely, the findings from our study highlight a
pro-inflammatory role for CD11b expressed by DCs that
actively promotes T cell activation. Expression of both
total and active CD11b was significantly increased in
cDC2 cells in the RA joint compared with PB, whilst ac-
tive CD11b expression was elevated in matDCs com-
pared with tolDCs. However, stimulation of PB DCs did
not model this result, potentially due to limitations with
the in vitro system, differences between DCs in healthy
controls compared with RA patients, or that the upregu-
lation of CD11b requires long-term (chronic) rather than
short-term stimulation. Importantly, however, blockade
of CD11b in moDC–T cell co-cultures reduced the ability
of matDCs to activate T cells. This appears to be a
novel finding. Indeed, several studies instead report a
regulatory role for CD11b in DCs: DC CD11b reportedly
inhibits T cell activation [14], whilst CD11b ligation in
DCs reduces pro-inflammatory cytokine production and
renders DCs more tolerogenic [28, 29]. Furthermore,
CD11b has repeatedly been described as a negative
regulator of Toll-like receptor (TLR) signalling [30, 31]
and was shown to induce production of the anti-
inflammatory cytokine IL-10 [32]. In mice, CD11b was
shown to have an essential role in preventing Th17
responses, in inducing oral tolerance and in resistance
to collagen-induced arthritis via the suppression of DC-
derived IL-6 [33, 34]. Similarly, ligation of CD11b on
human moDCs down-regulated pro-inflammatory cyto-
kine production and efficiently restricted Th17 cell ex-
pansion [35].
Despite these numerous reports of CD11b involve-
ment in immune regulation, our CD11b blockade data
clearly demonstrate a functional relevance of CD11b in
promoting T cell activation. In support of this, one previ-
ous study showed a reduction in T cell proliferation by
CD11b-deficient DCs due to the inability of DCs to
endocytose TLR4, indicating a role for CD11b as a posi-
tive regulator of TLR4 signalling [36]. However, as
CD11b blockade occurred after LPS-induced maturation
in our study, an impaired response via TLR4 is unlikely
to be responsible for the reduction in T cell priming
observed in the moDC–T cell co-cultures. Regardless,
our findings of increased CD11b expression in SF com-
pared with PB and in matDCs compared with tolDCs
provide strong evidence for a pro-inflammatory role for
CD11b in DCs.
One question that remains is how does CD11b
expressed by DCs promote T cell activation? We predict
that DC CD11b binds to T cell intercellular adhesion mole-
cules (ICAMs). This CD11b–ICAM interaction may (i) in-
crease the contact area and/or duration of DC–T cell
interactions, thus increasing signal strength through the T
cell receptor and co-stimulation (CD28) and increasing ac-
tivation [25]; or (ii) lead to direct signalling downstream of
ICAM that promotes T cell activation [37]. Note that these
two scenarios are not mutually exclusive.
Furthermore, the mechanism(s) responsible for the
opposing functions of CD11a and CD11b remains to be
determined. The ligand repertoire of CD11a and CD11b
is overlapping, but ligands that are unique to each integ-
rin do exist [26]. Thus, it is possible that the opposing
effects are due to binding to distinct ligands.
Alternatively, CD11a and CD11b may initiate distinct sig-
nalling pathways. The CD11a intracellular domain has
four identified phosphorylation sites, whereas CD11b
cytoplasmic sequence is much shorter, with only one
[38]. However, the possible functions of these CD11
chain phosphorylation sites remain unknown.
Our data raise the question of cause and effect: is in-
tegrin expression altered in response to environment
and/or is integrin expression by DCs actively contribu-
ting to the initiation or progression of inflammation and
autoimmunity? From the short-term stimulation of DCs
(Fig. 2) it is clear that expression of CD11a is down-
regulated in response to the local inflammatory milieu,
whilst a previous study points to a role for DC CD11a in
directly suppressing T cell responses [13]. For CD11b,
on the other hand, the in vitro stimulation data were un-
able to conclude whether expression is altered in re-
sponse to short-term treatment with pro- or anti-
inflammatory stimuli. However, blockade of DC CD11b
reduced T cell activation, suggesting that high CD11b
expression by DCs in the inflamed RA joint may be con-
tributing to disease progression. Thus, it is likely that
DCs alter their integrin expression pattern in response to
the local inflammatory milieu that drives their maturation
and inflammatory or tolerogenic potential. Importantly,
our study provides evidence that the integrin expression
profile of cDCs actively contributes to their functional
properties and influences CD4þ T cell responses, and
thus may be contributing to joint pathology in RA.
tolDCs are considered a promising strategy for the treat-
ment of RA [39] owing to their ability to produce immu-
noregulatory cytokines such as TGF-b and IL-10, induce
a tolerogenic T cell phenotype, and dampen immune
responses induced by matDCs [18, 23]. Knowledge of
integrin subunit expression and function in DCs in
steady-state, tolerogenic and inflammatory environments
may aid in the optimization of tolDC therapy. For ex-
ample, based on the findings from this study, we predict
DCs with high CD11a and low CD11b expression to be
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the most tolerogenic. Manipulation of integrins (e.g. by
providing integrin subunit agonists or antagonists [10]
during culture) may render tolDCs ‘better’ at tolerizing T
cells, and thereby aid our progress towards a cure for
RA.
In conclusion, we present for the first time data illus-
trating that b2 integrin family members, CD11a and
CD11b, on DCs have distinct roles in RA pathophysi-
ology: CD11a is highly expressed in steady state and
tolerogenic DCs, where it may exhibit an immunoregula-
tory function, whereas CD11b is highly expressed in ma-
ture inflammatory DCs such as those found in the RA
joint, and promotes T cell activation. Careful consider-
ation of integrin expression and function in DCs should
be taken when developing and optimizing DC-targeted
therapies.
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